A precision medicine approach to Alzheimer’s disease

By Jan Jarvis

Sid O'Bryant 1

 

Can an anti-inflammatory drug commonly used for headaches possibly treat or prevent Alzheimer’s disease?

The answer might depend on who’s taking the drug, according to Sid O’Bryant, PhD, Professor in the Center for Alzheimer’s and Neurodegenerative Disease Research at UNT Health Science Center.

There’s substantial evidence that non-steroidal anti-inflammatory drugs (NSAID) have a role in helping brain function, but research at UNTHSC suggests this is only for specific patient subgroups, said O’Bryant. He recently received a $3.5 million grant from the National Institute on Aging to study the use of anti-inflammatory drugs in treating specific subgroups of patients with Alzheimer’s disease.

“We know that inflammation is a huge deal in some, but not all patients,” he said. “With this project, we’ll be able to tell if an NSAID such as naproxen can be used to treat specific patients with Alzheimer’s or even possibly reduce the risk of the disease in some people over time.”

For the study, blood samples from approximately 10,000 patients who have completed clinical trials for treating and preventing Alzheimer’s disease will be examined. It is the first study to test the theory that there are subtypes of patients who benefit from specific drugs, he said. This study looks at those with high inflammation, which is about 20 percent of patients with Alzheimer’s.

Sid O'Bryant 2

“For those 20 percent with high inflammation, the anti-inflammatory drugs should help,” he said. “But for the 20 percent with low inflammation the drugs might not help at all or could make things worse.”

Although prior studies using drugs such as Aleve and Vioxx showed no clear effect on the disease, this study will examine blood samples from those trials to determine if the drugs worked for specific patients. If successful, this precision medicine approach will be expanded to look at different types of drugs that may be of benefit to different subgroups of patients.

Dr. O’Bryant’ s research focuses on specific subgroups of patients rather than trying to find a single miracle drug that cures everyone with Alzheimer’s disease. Previous trials have not been successful, but that was because they tried to treat everyone the same, he said.

“Most trials fail,” Dr. O’Bryant said. “But in reality, they didn’t fail. We just didn’t know who they worked for.

“I believe within five years this work is going to really change the field.”

Recent News

Abe Clark
  • Research
|Mar 28, 2024

Dr. Abe Clark honored with international research award

Abbot “Abe” Clark, PhD, FARVO, FAAO, regents professor of pharmacology and neuroscience in the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, has received the International Society for Eye Research 2024 Ernst H. Bárány Prize.   The awar...
Processed With Lensa With Pt12 Filter
  • Research
|Mar 28, 2024

Dr. Steven Romero receives American Physiological Society award for excellence in research

Dr. Steven Romero, associate professor of Physiology and Anatomy at the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, was named the 2024 Henry Pickering Bowditch Award Lecturer by the American Physiological Society. The lectureship is awarded to ...
Screenshot 2024 03 28 At 8.50.12 am
  • Our People
|Mar 28, 2024

Physical therapy student lands prestigious role in national organization

When Jonathan Hansen was an undergraduate intern at Texas Health Arlington Memorial Hospital, he encountered a man who had just suffered a stroke. The patient’s right side was completely paralyzed. Hansen, now a first-year student in The University of North Texas Health Science Center at Fort Wort...
Jackie In Dc
  • Our People
|Mar 27, 2024

Personalized Health and Well-Being student repays generosity through advocacy

In 2019, The University of North Texas Health Science Center at Fort Worth student Jacqueline Green said she felt hopeless. She became pregnant while experiencing hard financial times, and she didn’t have insurance. Compounding her stress was terrible grief. Her mother-in-law suddenly passed away,...